Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Webcasts


Play
How much do you have to reduce Lp(a) to achieve significant clinical benefit?
Play
Bempedoic acid: The new kid on the block
Play
Immunotherapies in homozygous FH: Alirocumab and evinacumab
Play
Remnant lipoproteins and impact of PCSK9 inhibition
Play
Genome-wide polygenic risk scores: Insights from ODYSSEY OUTCOMES
Play
Genetic risk scores: How much do they add?
Play
Inclisiran: Update on efficacy, dosing regimen, safety and COVT trial
Play
Lp(a): Findings in ODYSSEY OUTCOMES
Play
What’s new in very high-risk patients?
Play
Do the new ESC/EAS guidelines change your clinical practice? Acute coronary syndromes
Play
Lp(a): Risk factor or causal factor? A critical appraisal
Play
ODYSSEY OUTCOMES and stroke events
Play
Treat ischaemic stroke to target
Play
Endothelial LDL transcytosis in atherosclerosis
Play
Emerging lipid science: ApoE and chronic disease
Play
ODYSSEY OUTCOMES: Update
Play
New data from FOURIER and design of the VESALIUS-CV Trial
Play
PCSK9 Genetics: New Insights
Play Hepatic lipid metabolism: Storage vs secretion
Jan Boren Hepatic lipid metabolism: Storage vs secretion
Play Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins
Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins